Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Contineum Therapeutics stock last closed at $15.71, up 1.35% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Biotechnology industry by N/A percentage points. Contineum Therapeutics stock is currently +18.39% from its 52-week low of $13.27, and -2.36% from its 52-week high of $16.09.
At the moment, there are 25.72M CTNM shares outstanding. The market value of CTNM is $404.11M. In the last 24 hours, 50,675 CTNM shares were traded.
You need an online brokerage account to access the NASDAQ market and buy CTNM stock.
Based on our analysis, eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by opening an account with eToro today.
Open eToro AccountNow that you've chosen the right brokerage, you'll need to fill out some personal info so you are able to buy CTNM today.
Now that you've created your account on app for stock market, your next step is to transfer the money for your investment:
Watch this video walkthrough for more details depositing money into your new brokerage account.
After you have chosen the best place to buy Contineum Therapeutics stock, it's important to research their stock before you invest, so you can wrap your head around the risk and upside.
WallStreetZen was built to help everyday investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CTNM's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge CTNM's fair value.
You can access additional valuation research on CTNM's stock here.
Out of 3 Wall Street analysts who give forecasts on CTNM, the consensus analyst rating on Contineum Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Contineum Therapeutics stock forecast page.
In the last year, executives and large shareholders at CTNM have not bought or sold any shares.
Learn more about who owns CTNM stock here.
No, Contineum Therapeutics doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two main order types:
Click the Open button and eToro will place the order.
If you require more help buying stocks on eToro, click the helpful video below:
Now that you own some shares in CTNM, you'll want to keep up with your new shares.
Create a watchlist to get notified of the latest news about your CTNM stock.
To summarize, here are the 6 steps to buy stock in Contineum Therapeutics:
If you are looking for a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Contineum Therapeutics, add CTNM to your watchlist by clicking the button below.